Introduction: Early dry powder inhalers (DPIs) were designed for low drug doses in asthma
and COPD therapy. Nearly all concepts contained carrier-based formulations and lacked …

Messenger RNAs (mRNAs) were previously shown to have great potential for preventive
vaccination against infectious diseases and therapeutic applications in the treatment of …

Pulmonary delivery of messenger RNA (mRNA) has considerable potential as therapy or
vaccine for a range of lung diseases. Inhaled dry powder formulation of mRNA is particularly …

With the rapidly growing popularity and sophistication of inhalation therapy, there is an
increasing demand for tailor-made inhalable drug particles capable of affording the most …

A wide range of dry powder inhaler (DPI) devices are currently available on the market to
deliver drugs into lungs with a view to maximise drug delivery with low variability. DPIs also …

Dry powder inhalers (DPIs) can be used with a wide range of drugs such as small molecules
and biologics and offer several advantages for inhaled therapy. Early DPI products were …

The delivery efficiency of dry-powder products for inhalation is dependent upon the drug
formulation, the inhaler device, and the inhalation technique. Dry powder formulations are …

Inhalation of drug aerosols is a modern pathway to combat lung diseases. It is also
becoming the preferred route for insulin delivery, pain management, cancer therapy, and …

Many years of research have not led to a profound knowledge of the mechanisms involved
in the formulation and dispersion of carrier based mixtures for inhalation. Although it is well …

The performance of dry powder aerosols for the delivery of drugs to the lungs has been
studied extensively in the last decade. The focus for different research groups has been on …